



Emerging growth company [  ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

---

Item 7.01. Regulation FD Disclosure.

A copy of the investor presentation that Pain Therapeutics, Inc. used in conjunction with today's October 04, 2018 conference call is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibit No. Description.

99.1      Pain Therapeutics, Inc. Investor presentation dated October 04, 2018

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Pain Therapeutics, Inc.

Date: October 04, 2018 By: /s/ Remi Barbier  
Remi Barbier  
Chairman of the Board of Directors,  
President and Chief Executive Officer

---